Laparoscopic and percutaneous approaches have similar short-term efficacy in treating renal tumors. Laparoscopic (LAP) and CT-guided percutaneous (PERC) cryoablation for renal tumors result in similar ...

"For patients who have larger tumors but can't undergo surgery, this approach could be more effective," interventional radiologist Yolanda Bryce, M.D. said Getty Breast cancer patients who were ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...

ORLANDO -- Cryoablation without excision for low-risk, early-stage breast cancer may be an option for women over 60, 5-year follow-up results from the ICE3 trial showed. At a mean follow-up of 54.2 ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...

Percutaneous cryoablation may provide a safe and effective treatment option for patients with renal tumors, new findings suggest. David J. Breen, MD, and colleagues from University Hospitals of ...

Study was conducted in Spain with women who declined standard of care surgery ProSense is approved for the treatment of breast cancer throughout the European Union All patients were diagnosed with ...

Cryoablation for breast cancer is now included in proposed medical society guidelines for the approved patient population CAESAREA, Israel, Feb. 11, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ...

IceCure Medical has received US Food and Drug Administration (FDA) marketing authorisation for its ProSense cryoablation system to treat breast cancer. The FDA's approval requires IceCure to conduct a ...

PFA was noninferior to cryoablation for first recurrence of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation. Tissue-selective energy delivery and short application times offer ...